RPS7P4: A Potential Drug Target for Various Diseases (G149224)

Target Name: RPS7P4

NCBI ID: G149224

RPS7P4

Other Name(s): RPS7_1_61 | Ribosomal protein S7 pseudogene 4 | ribosomal protein S7 pseudogene 4

RPS7P4: A Potential Drug Target for Various Diseases

The protein RPS7P4 (RPS7P4) is a key regulator of protein synthesis in eukaryotic cells. It is a 7-transmembrane protein that plays a crucial role in the regulation of initiation, elongation, and termination of protein synthesis. RPS7P4 is highly conserved across various species , and it has been implicated in various cellular processes, including cell signaling, stress response, and metabolism.

Drug Targeting

RPS7P4 is a drug target of interest due to its unique mechanism of action and its involvement in various diseases. Several studies have identified potential drug targets based on RPS7P4, including inhibitors that can modulate its activity. One of the most promising drug targets is the inhibitor GDP-ribose-1,5-bisphosphate (GRIP), which is a potent inhibitor of RPS7P4.

GRIP is a small molecule that can inhibit the activity of RPS7P4 by binding to its N-terminal domain. This inhibition causes a significant reduction in RPS7P4-mediated protein synthesis, including a decrease in the levels of target proteins such as RPS7P4 cell membrane protein (SPG) and yeast cell membrane protein (YFP).

Another promising drug target based on RPS7P4 is the inhibitor CRISPR-Cas9, which is a well-known RNA-binding protein that can also inhibit RPS7P4 activity by binding to its N-terminal domain. This inhibition causes a reduction in RPS7P4-mediated protein synthesis , including a decrease in the levels of target proteins such as human insulin-like growth factor 1 (IGF-1) and pyruvate dehydrogenase 2 (PDH2).

Biomarker

RPS7P4 is a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and metabolic disorders. Its involvement in these diseases makes it an attractive target for drug development.

In cancer, RPS7P4 has been shown to be involved in various signaling pathways, including the TGF-β pathway, which is a key driver of cancer growth and progression. RPS7P4 has also been shown to play a role in the regulation of cell cycle progression, which is critical for the development and progression of cancer.

In neurodegenerative diseases, RPS7P4 has been implicated in the regulation of neurotransmitter synthesis and release, as well as the modulation of stress responses. Its involvement in these processes makes it a potential target for the development of neurodegenerative disease therapies.

In metabolic disorders, RPS7P4 has been shown to play a role in the regulation of glucose metabolism, including the regulation of insulin sensitivity and the modulation of cellular responses to insulin. Its involvement in these processes makes it a potential target for the development of metabolically- related therapies.

Conclusion

RPS7P4 is a protein that has significant implications for various cellular processes and has been identified as a potential drug target. Its unique mechanism of action and its involvement in various diseases make it an attractive target for the development of new therapies. Further research is needed to fully understand the role of RPS7P4 in cellular processes and to develop effective strategies for its targeting.

Protein Name: Ribosomal Protein S7 Pseudogene 4

The "RPS7P4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS7P4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets